Natural Matrix Protein
NMP
Evaluating Natural Matrix Protein (NMP) in Lumbar Spinal Fusion
1 other identifier
observational
100
1 country
1
Brief Summary
This clinical study is a non-randomized, consecutive, single-center, retrospective-prospective investigation of patients who received NMP bioimplant (Induce Biologics, Tampa, FL) in lumbar spinal fusion procedures. The purpose of this study is to assess the radiographic, clinical, and safety outcomes of Natural Matrix Protein (NMP) as a graft alternative in lumbar fusion procedures. Utilizing the Hospital for Special Surgery's EPIC database under Institutional Review Board approval, all patients with symptomatic lumbar degenerative disc disease who failed conservative management at up to four vertebral levels between L1-S1 between February 2024 and December 2025 will be reviewed. The inclusion criteria for the study will be adult patients (≥ 18 years old) who underwent lumbar fusion with an NMP graft and interbody cage. The exclusion criteria will include previous lumbar fusion attempts, active malignancy, concurrently under chemotherapy, active infection at time of surgery, mentally compromised, and trauma to the operated region. It is expected approximately 100 patients will fit the inclusion/exclusion criteria. The objective of the study is to evaluate the clinical outcomes of the subjects treated with NMP
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2025
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 18, 2025
CompletedFirst Submitted
Initial submission to the registry
October 15, 2025
CompletedFirst Posted
Study publicly available on registry
October 20, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 17, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 17, 2027
October 20, 2025
March 1, 2025
2 years
October 15, 2025
October 15, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Radiographs
Radiographic: Imaging assessments will be performed by an independent imaging reviewer. The reviewer will be a musculoskeletal radiologist trained in the schedule of imaging assessments and classification systems for performing each assessment. The reviewer will not have access to clinical outcome data. Plain lateral radiographs at baseline, immediate postoperative, 6-month follow-up, and 1-year follow-up. All radiological measurements will be made using Sectra IDS7 (Sectra AB, Linköping, Sweden). Fusion status on radiographs will be graded at each treated segment from an analysis of three components: bridging bone between the vertebral bodies, angular motion, and translational motion. Fusion Status measured on radiographs was derived from the qualitative assessment of bridging bone and the quantitative assessments of angular and translational Motion. The following grading system was implemented: Not Fused: Absence of bridging bone from endplate to endplate
From May 2025 until May 2027
Study Arms (1)
Adult patients (≥ 18 years old) who underwent lumbar fusion
NMP graft with interbody cage
Interventions
surgical procedure
Eligibility Criteria
hospital patients
You may qualify if:
- \. Adult patients (≥ 18 years old) who underwent lumbar fusion with an NMP graft and interbody cage
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital for Special Surgery
New York, New York, 10021, United States
Related Publications (4)
D'Souza M, Macdonald NA, Gendreau JL, Duddleston PJ, Feng AY, Ho AL. Graft Materials and Biologics for Spinal Interbody Fusion. Biomedicines. 2019 Sep 26;7(4):75. doi: 10.3390/biomedicines7040075.
PMID: 31561556BACKGROUNDRathbone J, Rackham M, Nielsen D, Lee SM, Hing W, Riar S, Scott-Young M. A systematic review of anterior lumbar interbody fusion (ALIF) versus posterior lumbar interbody fusion (PLIF), transforaminal lumbar interbody fusion (TLIF), posterolateral lumbar fusion (PLF). Eur Spine J. 2023 Jun;32(6):1911-1926. doi: 10.1007/s00586-023-07567-x. Epub 2023 Apr 18.
PMID: 37071155BACKGROUNDMartin BI, Mirza SK, Spina N, Spiker WR, Lawrence B, Brodke DS. Trends in Lumbar Fusion Procedure Rates and Associated Hospital Costs for Degenerative Spinal Diseases in the United States, 2004 to 2015. Spine (Phila Pa 1976). 2019 Mar 1;44(5):369-376. doi: 10.1097/BRS.0000000000002822.
PMID: 30074971BACKGROUNDFehlings MG, Tetreault L, Nater A, Choma T, Harrop J, Mroz T, Santaguida C, Smith JS. The Aging of the Global Population: The Changing Epidemiology of Disease and Spinal Disorders. Neurosurgery. 2015 Oct;77 Suppl 4:S1-5. doi: 10.1227/NEU.0000000000000953.
PMID: 26378347BACKGROUND
MeSH Terms
Interventions
Study Officials
- STUDY DIRECTOR
Celeste Abjornson, PhD
Hospital for Special Surgery, New York
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 24 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD
Study Record Dates
First Submitted
October 15, 2025
First Posted
October 20, 2025
Study Start
March 18, 2025
Primary Completion (Estimated)
March 17, 2027
Study Completion (Estimated)
September 17, 2027
Last Updated
October 20, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will not share
data is aggragated for reporting